SGLT2is have been demonstrated to reduce the production of inflammatory cytokines, such as TNF-α, MCP-1, IL-1β, and IL-6, and to attenuate the activation of the NLRP3 inflammasome in MASLD animal models [182]. The gene discussed is CCL2; the disease is metabolic dysfunction-associated steatotic liver disease.